News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Preclinical study findings propels Entremed (


Posted on: 04/22/2003

Preclinical study findings propels Entremed

(ENMD) By Michael Baron

Entremed (ENMD) is soaring more than 125 percent to $2.43 following news that the a study of the company's lead drug candidate Panzem found that its anti-tumor and anti-angiogenesis activity is dependent on its ability to inhibit microtubules and hypoxia inducible factor, or HIF. The company said the data establishes Panzem as a small molecule inhibitor of HIF, which is 'over-expressed in more than 70 percent of human cancers and metastases.'


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740